Prototype analysis of a low-power, small-scale wearable medical device
Online veröffentlicht: 04. Jan. 2025
Seitenbereich: 169 - 176
Eingereicht: 20. Nov. 2024
DOI: https://doi.org/10.2478/joeb-2024-0020
Schlüsselwörter
© 2024 Pablo Dutra da Silva et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
The wearable device is rapidly becoming a crucial tool in health monitoring, medical diagnostics, and selfquantification, especially for athletes and health enthusiasts. This type of device refers to anything worn by an individual that has the capability to measure biological signals and activity patterns. Typically designed as wristbands, smartwatches, chest straps, shoes, socks, or glasses, wearables have transitioned from primarily tracking activities such as sleep, walking, and running to functioning as medical instruments capable of measuring various vital signs. Early versions of wearable devices were not suitable for medical diagnostics; however, recent scientific research has begun exploring their potential to detect correlations between activity patterns—linked to life-style—and specific cardiovascular diseases. The goal for wearable technology is to provide non-invasive, real-time monitoring for patients at home or in ambulatory settings, offer early alerts or diagnoses for healthy individuals, and enhance performance for athletes [1, 2].
Recent technological advancements have expanded the capabilities of wearables by incorporating additional sensors that measure biological signals such as heart rate, blood oxygen levels, electrocardiograms, and skin temperature. Some of these devices are commercially available, including those from companies like Apple, Samsung, Xiaomi, Fitbit, and Garmin, while others are still in the research and development phase [1, 2]. A significant area of research involves utilizing these commercial wearable models for diagnosing cardiovascular problems [1, 2]. However, for biological parameters like glucose, there is no non-invasive commercial solution that matches the performance of the gold standard, which is an invasive electrochemical method [3, 4, 5]. This gap in technology supports the ongoing scientific efforts to develop non-invasive glucose measurement systems [3, 4, 5, 6]. The minimally invasive CGM (Continuous Glucose Monitor) from Abbott Labs (FreeStyle Libre) has improved diabetes management but differs from wearables in its function, as it lacks the multi-functional capabilities of a wearable device. Furthermore, CGM requires frequent electrode replacements, making it costly for patients, unlike non-invasive electrodes, which do not require such replacements.
Diabetes Mellitus is a chronic condition characterized by inadequate insulin production or absorption, a hormone responsible for regulating blood glucose by breaking down glucose molecules and providing energy to the body [7]. Managing diabetes involves constant monitoring of blood glucose levels, enabling patients to take effective actions to control their glucose levels and mitigate the disease’s complications [4, 5, 6]. Currently, electrochemical sensors used in glucose meters require blood samples, which must be placed on reagent strips that are then inserted into an electronic device to determine glucose concentration. While this method remains the gold standard for selfmonitoring [4, 5, 6], it is painful and unhygienic, requiring frequent finger pricks to obtain blood. Additionally, diabetes patients must perform this procedure multiple times a day.
Consequently, a non-invasive glucose monitor would offer significant benefits for diabetes patients, including pain reduction, infection prevention, and cost savings, especially if the monitor is designed as a wearable device that provides automatic measurements with accuracy comparable to the gold standard [8, 9].
A wearable glucose measurement system should, like other wearables, feature ultra-low voltage supply, minimal power consumption, compact size, and high accuracy [10, 11, 12, 13]. These characteristics are typically achieved through very large-scale integration (VLSI) technologies such as complementary metal-oxide semiconductor (CMOS), which is a standard method for fabricating integrated circuits (ICs). Several research papers propose different IC designs for biomedical applications, including those for glucose monitoring [8, 12]. One major challenge in wearables is power consumption, which impacts battery usage. As a result, researchers have been investigating energy harvesting techniques to power medical wearables more efficiently [10].
To advance the development of non-invasive, wearable blood glucose monitoring for diabetics, this work continues the research from [14, 15, 16], focusing on an IC design powered by batteries. This research direction is essential since Teixeira’s [16] earlier work used discrete components on a prototype printed circuit board (PCB) to validate the EGluco project [17]. The initial prototype consists of two connected boxes: the first holds the sensors, bioimpedance electrodes, and signal conditioning circuits, while the second contains an STM32 dev kit, a Bluetooth module, a 9V battery, and a medical power supply to deliver ±5
This paper presents the design considerations and outcomes of a low-power, single-supply Enhanced Howland Current Source and an instrumentation amplifier for a wearable glucose monitor using bioimpedance spectroscopy as one of the analysis techniques. Section 2 discusses the current prototype, while Section 3 introduces the EHCS for low-voltage power supplies and the instrumentation amplifier. Finally, Section 4 presents the test results for both circuits presented.
A non-invasive blood glucose meter based on bioimpedance spectroscopy has been developed as part of the EGluco project [17]. Several aspects of this development are discussed in the works [14, 15, 16]. Analytical models for determining blood glucose levels from photoplethysmography analysis are outlined in [15], while models for electrical bioimpedance analysis are provided in [14]. Despite the significance of these analytical models, current development is shifting towards the application of artificial intelligence (AI) for glucose level estimation. Although the first prototype was not suitable as a wearable device, it provides essential data for training AI algorithms. Furthermore, the initial prototype is crucial for defining system specifications, assessing the sensitivity of glucose measurements to factors such as skin temperature, humidity, heart rate, and oxygen saturation, and verifying the connections between different parts of the system.
The work presented in [16] details a system based on printed circuit board (PCB) technology, utilizing commercial integrated circuits (ICs) and discrete passive components. In Figure 1, some components of the system are visible, including two PCBs (PCB1 and PCB2), a chassis for sensor positioning, and the STM32 evaluation board. A DC ±5

System diagram for the current device under development.
This system analysis can be conducted by referring to Figure 2, which organizes the system blocks similarly to the physical layout shown in Figure 1. PCB1 (indicated by green with dashed borders) is designed to serve as the soldering base for the sensors and actuators, connecting the analog signal conditioning circuitry and control signals passing through PCB2. For bioimpedance analysis, four terminals (EL1, EL2, EL3, and EL4) are identified in Figure 1 and numbered 1 through 4 in Figure 2. Terminals 1 and 2 are used to inject current into the user’s skin. Terminal 2 connects to a shunt resistor for current measurement. Terminals 3 and 4 are used to measure the voltage at a position displaced from the current injection points, which is necessary for evaluating the skin impedance. Additionally, four LEDs and a photodiode for the photoplethysmography process are attached to PCB1, along with temperature and humidity sensors. These sensors are used to measure oxygen saturation, skin temperature, and humidity, which help detect the measurement context. This contextual information is crucial for understanding skin conditions and other variables that could impact glucose measurement via bioimpedance analysis. All of these sensors and actuators are connected to the analog conditioning circuitry on PCB2 via a pin header.

System diagram for the current device under development.
Analog signal conditioning and power supply management circuitry are housed on PCB2 (indicated by the red dashed border). This PCB is also responsible for controlling signals between the microcontroller and the sensors and other circuits. A voltage regulator on PCB2 converts an external ±12
The outputs of these amplifiers are connected to the STM32 evaluation kit (represented in light blue with dotted borders), where the firmware processes all of the signals. This evaluation board requires a 3.3
The bioimpedance spectroscopy system must meet the following criteria: a single power supply of +3.3
The Enhanced Howland Current Source (EHCS) is shown in Fig. 3. This configuration is commonly used in both time and frequency domain impedance spectroscopy for injecting current into the sample [18, 19, 20, 21, 22]. When the resistors are properly matched, the EHCS is known for its high output impedance. As a result, resistor tolerances of less than 0.1% are necessary when using discrete resistors [23, 24, 25].

Enhanced Howland Current source Schematic.
In both frequency and time domain spectrographic analysis, the EHCS is suitable for generating sinusoidal and pseudo-random current signals. It is important to carefully evaluate the operational amplifier’s gainbandwidth product and slew rate when used in timedomain BIS. The design equations for the EHCS are well-documented in the impedance spectroscopy literature and are not repeated here. The output current, as defined by equation (1), depends on the input differential voltage and resistor R1 when
The OPA2354 operational amplifier provides a gainbandwidth product of 250
The schematic diagram of the instrumentation amplifier is shown in Fig. 4. It can be observed that a topology using three operational amplifiers was chosen. This decision was made because it was difficult to find monolithic instrumentation amplifiers with low supply voltages that had a slew rate compatible with the application available on the market. For a supply voltage of 3.3V, only operational amplifiers were found. Therefore, the topo-logy using three operational amplifiers from the OPA4354 chip, which has the same electrical characteristics as the OPA2354 used for the improved Howland current source, was selected.

Instrumentation Amplifier Schematic.
This topology is necessary because the input impedance of the instrumentation amplifier is higher than that of a difference amplifier with only one operational amplifier. The resistor values chosen are: R1 to R7 = 10 KΩ, R8 and R9 = 10 MΩ, and the decoupling capacitors C1 and C2 = 10
The conducted research is not related to either human or animal use.
The data shown in Fig. 5 (A), Fig. 5 (B), and Fig. 5 (C) were obtained through a Cadence PSPICE simulation using the op-amp macromodel supplied by the manufacturer, specifically for the EHCS scenario. The correlation between the output DC current and the output DC voltage sweep is derived when a voltage source is connected to the load electrodes, as illustrated in Fig. 5 (A) and Fig. 5 (B). These experiments demonstrate the allowable output voltage swing. Fig. 5 (A) and Fig. 5 (B) indicate that the EHCS allows a swing of +1.6 V for a power supply voltage of +3.3

DC simulation results for the low power supply design.
Although the EHCS achieved a DC output impedance of approximately 200
CC output current (in
Topology | Iout (0< |
Iout (1.8< |
---|---|---|
EHCS | 250.118 to 250.121 | 249.97 to 250.12 |
The results from the AC analysis of the output impedance are presented in Fig. 6. This analysis was conducted using the same circuit configuration as the DC analysis, with the load replaced by a signal generator in SPICE for an AC sweep analysis. The EHCS performs well from DC to 1

Output impedance versus frequency in AC analysis.
The tests were performed with a load of 1

Simulation vs test output current comparison for 2 :
As observed in Fig. 6, even at 1

Simulation vs test output current comparison for 1
For the tests with the instrumentation amplifier, a load of 1

Instrumentation amplifier test with a 1
A test using an equivalent Cole model with two 1 kΩ resistors and a 1 nF capacitor was carried out and the results are shown in Fig. 10. All the conditions were maintained with respect to the test shown in Fig. 4 except the load. Fig. 10 shows that the amplifier maintains its linearity and the gain designed for the Cole load up to a frequency of 100 kHz. Both the test whose results are shown in Fig. 4 and the test whose results are shown in Fig. 10 demonstrate that the analog front end for electrical impedance spectroscopy is capable of taking accurate measurements up to a frequency of 100kHZ.

Instrumentation amplifier test with a Cole impedance for a 100
The tests carried out with frequencies below 100 kHz maintained the same conclusions as those presented for Fig. 4 and Fig. 10. For frequencies up to 1
In addition to the current source described in this study, several modifications have simplified the power supply system shown in Fig. 2. For example, the microcontroller system has been made more compact, now operating on the same supply voltage as the entire system, with a built-in Bluetooth connection. Moreover, all components were designed using the smallest available packages. In this revised configuration, the entire system is powered by a single supply voltage from a battery, leading to a reduction in device volume. The entire measurement system is now mounted on a 5 × 5 cm PCB, as seen in Fig. 11, where (A) shows the top view of the system with its components and (B) shows the bottom view, including the bioimpedance electrodes, LEDs, and photodiode.

Shrink prototype (A) top view and (B) bottom view.
The development of a low voltage battery supplied and instrumentation amplifier for electrical bioimpedance system was presented as a key contribution to reducing both the power consumption and the volume of a non-invasive blood glucose monitoring system. These and other improvements have led to a reduction in the overall system size, making it more suitable for future wearable applications.
However, to transform this project into a practical wearable device with minimal battery consumption, it must be miniaturized to a microscopic scale. Achieving this will require the development of an integrated circuit using CMOS technology. The initial progress toward this objective includes the work presented here as well as the research detailed in [26].
The device that incorporates the current source and the instrumentation amplifier is currently undergoing testing, and the results can be accessed through the EGluco project dashboard, available at [17].
Both simulation and bench test results confirm that the current source is robust and precise across temperature and component variations. Additionally, it has demonstrated the capability to efficiently handle rectangular signals up to 1